PHAR
Income statement / Annual
Last year (2024), Pharming Group N.V.'s total revenue was $286.89 M,
an increase of 16.95% from the previous year.
In 2024, Pharming Group N.V.'s net income was -$10.64 M.
See Pharming Group N.V.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$286.89 M |
$245.32 M |
$205.62 M |
$189.85 M |
$228.39 M |
$189.33 M |
$154.58 M |
$107.52 M |
$16.69 M |
$11.84 M |
| Cost of Revenue |
$34.17 M
|
$25.21 M
|
$17.56 M
|
$20.18 M
|
$25.34 M
|
$23.92 M
|
$25.37 M
|
$14.93 M
|
$4.93 M
|
$5.25 M
|
| Gross Profit |
$252.72 M
|
$220.10 M
|
$188.06 M
|
$169.67 M
|
$203.06 M
|
$165.41 M
|
$129.20 M
|
$92.59 M
|
$11.77 M
|
$6.59 M
|
| Gross Profit Ratio |
0.88
|
0.9
|
0.91
|
0.89
|
0.89
|
0.87
|
0.84
|
0.86
|
0.7
|
0.56
|
| Research and Development Expenses |
$80.28 M
|
$68.91 M
|
$52.53 M
|
$67.18 M
|
$41.46 M
|
$31.78 M
|
$33.04 M
|
$22.38 M
|
$16.18 M
|
$15.50 M
|
| General & Administrative Expenses |
$68.17 M
|
$80.68 M
|
$46.02 M
|
$35.30 M
|
$14.42 M
|
$21.19 M
|
$13.98 M
|
$7.17 M
|
$4.88 M
|
$4.09 M
|
| Selling & Marketing Expenses |
$114.70 M
|
$6.82 M
|
$85.80 M
|
$56.75 M
|
$55.55 M
|
$44.71 M
|
$39.51 M
|
$37.70 M
|
$3.19 M
|
$1.19 M
|
| Selling, General & Administrative Expenses |
$182.86 M
|
$87.50 M
|
$131.82 M
|
$92.05 M
|
$69.97 M
|
$65.90 M
|
$53.49 M
|
$44.86 M
|
$8.07 M
|
$5.28 M
|
| Other Expenses |
-$2.10 M
|
$69.08 M
|
-$14.52 M
|
-$2.50 M
|
$9.54 M
|
-$487,274.85
|
-$684,000.00
|
-$790,000.00
|
-$335,000.00
|
-$147,000.00
|
| Operating Expenses |
$261.04 M
|
$225.49 M
|
$169.83 M
|
$156.72 M
|
$120.97 M
|
$97.19 M
|
$85.74 M
|
$66.30 M
|
$23.91 M
|
$20.62 M
|
| Cost And Expenses |
$295.21 M
|
$250.70 M
|
$187.39 M
|
$176.91 M
|
$146.31 M
|
$121.11 M
|
$111.12 M
|
$81.23 M
|
$28.83 M
|
$25.87 M
|
| Interest Income |
$0.00
|
$3.53 M
|
$85,000.00
|
$14.23 M
|
$769,949.00
|
$1.13 M
|
$20,590.00
|
$3,599.11
|
$5,258.51
|
$130,102.00
|
| Interest Expense |
$0.00
|
$5.96 M
|
$5.36 M
|
$5.92 M
|
$6.40 M
|
$13.35 M
|
$16.37 M
|
$21.28 M
|
$3.77 M
|
$135,569.00
|
| Depreciation & Amortization |
$15.51 M
|
$15.93 M
|
$13.19 M
|
$19.61 M
|
$8.31 M
|
$5.80 M
|
$7.50 M
|
$4.10 M
|
$795,086.00
|
-$716,113.09
|
| EBITDA |
$7.19 M |
$9.88 M |
$33.53 M |
$48.78 M |
$92.11 M |
$71.46 M |
$50.98 M |
-$39.81 M |
-$13.88 M |
-$14.75 M |
| EBITDA Ratio |
0.03
|
0.04
|
0.16
|
0.25
|
0.4
|
0.4
|
0.33
|
-0.37
|
-0.84
|
-1.25
|
| Operating Income Ratio |
-0.03
|
-0.02
|
0.09
|
0.15
|
0.36
|
0.36
|
0.28
|
0.24
|
-0.73
|
-1.19
|
| Total Other Income/Expenses Net |
$104,253.00
|
-$7.13 M
|
-$3.25 M
|
-$4.76 M
|
-$18.33 M
|
-$15.94 M
|
-$37.01 M
|
-$129.09 M
|
-$6.31 M
|
$4.07 M
|
| Income Before Tax |
-$8.22 M
|
-$12.01 M
|
$14.99 M
|
$22.03 M
|
$47.47 M
|
$52.29 M
|
$980,324.00
|
-$107.25 M
|
-$18.44 M
|
-$10.89 M
|
| Income Before Tax Ratio |
-0.03
|
-0.05
|
0.07
|
0.12
|
0.21
|
0.28
|
0.01
|
-1
|
-1.1
|
-0.92
|
| Income Tax Expense |
$2.43 M
|
-$1.46 M
|
$1.31 M
|
$6.76 M
|
$6.83 M
|
$11.74 M
|
-$27.61 M
|
-$11.33 M
|
$3.77 M
|
$851,682.00
|
| Net Income |
-$10.64 M
|
-$10.55 M
|
$13.67 M
|
$16.00 M
|
$37.75 M
|
$40.54 M
|
$28.59 M
|
-$95.92 M
|
-$18.44 M
|
-$10.89 M
|
| Net Income Ratio |
-0.04
|
-0.04
|
0.07
|
0.08
|
0.17
|
0.21
|
0.18
|
-0.89
|
-1.1
|
-0.92
|
| EPS |
-0.0154 |
-0.0145 |
0.0168 |
0.02 |
0.0464 |
0.052 |
0.0352 |
-0.1536 |
-0.0352 |
-0.0216 |
| EPS Diluted |
-0.0154 |
-0.0145 |
0.0152 |
0.0184 |
0.044 |
0.048 |
0.0352 |
-0.1536 |
-0.0352 |
-0.0216 |
| Weighted Average Shares Out |
$689.19 M
|
$657.03 M
|
$883.93 M
|
$876.44 M
|
$853.42 M
|
$841.90 M
|
$816.91 M
|
$625.52 M
|
$519.23 M
|
$510.85 M
|
| Weighted Average Shares Out Diluted |
$689.19 M
|
$657.02 M
|
$883.93 M
|
$876.44 M
|
$853.42 M
|
$841.90 M
|
$816.91 M
|
$625.52 M
|
$519.23 M
|
$510.85 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
